Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

References

• Zevalin (ibritumomab tiuxetan) prescribing information. Physicians' Desk Reference59th edn. Thomson PDR, Montvale, NJ 2005; 1738–1743
   Google Scholar
• Anderson K C, Bates M P, Slaughenhoupt B L, Pinkus G S, Schlossman S F, Nadler L M. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424–1433
   PubMed Web of Science ®Google Scholar
• Press O W. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999; 26: 58–65
   PubMed Web of Science ®Google Scholar
• Wiseman G A, Kornmehl E, Leigh B, Erwin W D, Podoloff D A, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44: 465–474
   PubMed Web of Science ®Google Scholar
• Wiseman G A, Murray J I, Gordon L I, Emmanouilides C. Impact of metabolic and pharmacokinetic variability on dosing methodology for radioimmunotherapy (RIT) in patients with CD20 + B-cell non-Hodgkin's lymphoma. J Nucl Med 2003; 44: 415P
   Web of Science ®Google Scholar
• Witzig T E, White C A, Gordon L I, Wiseman G A, Emmanouilides C, Murray J L, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263–1270
   PubMed Web of Science ®Google Scholar
• Siegel A B, Leonard J P. Patient selection and safety in treatment with yttrium 90 ibritumomab tiuxetan. Ibritumomab Tiuxetan (Zevalin) in Non-Hodgkin's Lymphoma: Clinical Background, Practical Considerations, and Case Studies, B D Cheson. The Oncology Group, New York, NY 2003; 61–69
   Google Scholar
• Gordon L I, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 + B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103: 4429–4431
   PubMed Web of Science ®Google Scholar
• Witzig T E, White C A, Wiseman G A, Gordon L I, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793–3803
   PubMed Web of Science ®Google Scholar
• Wiseman G A, Gordon L I, Multani P S, Witzig T E, Spies S, Bartlett N L, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336–4342
   PubMed Web of Science ®Google Scholar
• Witzig T E, Flinn I W, Gordon L I, Emmanouilides C, Czuczman M S, Saleh M, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269
   PubMed Web of Science ®Google Scholar
• Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463
   PubMed Web of Science ®Google Scholar
• Wiseman G A, Witzig T E. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Cancer Biother Radiopharm 2005; 20: 185–188
   PubMed Web of Science ®Google Scholar
• Ansell S M, Schilder R J, Pieslor P C, Gordon L I, Emmanouilides C, Czuczman M S, et al. Subsequent antilymphoma therapies are feasible after radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). Blood 2003; 102: 308
   Google Scholar
• Ansell S M, Ristow K M, Habermann T M, Wiseman G A, Witzig T E. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3885–3890
   PubMed Web of Science ®Google Scholar
• Ansell S M, Schilder R J, Pieslor P C, Gordon L I, Emmanouilides C, Vo K, et al. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan (Zevalin) are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma 2004; 5: 202–204
   PubMedGoogle Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Risher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Schilder R J, Witzig T, Gordon L, Emmanouilides C E, Bartlett N L, Flinn I W, et al. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma. Proc Am Soc Clin Oncol 2002; 21: 267
   Google Scholar
• Morschhauser F, Huglo D, Martinelli G, Paganelli G, Zinzani P L, Hadjiyiannakis D, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. Blood 2004; 104: 41
   Web of Science ®Google Scholar
• Kaminski M S, Tuck M, Estes J, Kolstad A, Ross C W, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441–449
   PubMed Web of Science ®Google Scholar
• Sweetenham J W, Dicke K, Arcaroli J, Kogel K, Rana T M, Rice L. Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood 2004; 104: 702
   Google Scholar
• Shipley D L, Spigel D R, Carrell D L, Dannaher C, Greco F A, Hainsworth J D. Phase II trial of rituximab and short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2004; 23: 560
   Google Scholar